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Abstract
With the recent breakthroughs in G protein-coupled receptor structure, one can now compare
experimentally determined structures with the most recent modeling and docking methods. A
community-wide blind prediction experiment (GPCR Dock 2008) was conducted in coordination
with the publication of the human adenosine A2A receptor bound to the ligand ZM241385 crystal
structure (Science 322, 1211 (2008)). Twenty-nine participating groups submitted 206 models that
were evaluated for the accuracy of the ligand binding mode and the overall receptor model. Several
new insights emerged including the critical importance of disulfide bonds in the extracellular loops,
helix residue registry, and domain knowledge.
Introduction
Molecular modeling has a pertinent role in rational drug discovery and design1, 2. Reliable
three-dimensional models can provide valuable insights into basic principles of molecular
recognition and aid in the structure-based drug design approach to lead finding and
optimization3. G protein-coupled receptors (GPCRs) are membrane proteins involved in signal
transduction pathways and are important therapeutic targets for numerous diseases4, 5. As such,
significant structure prediction efforts using methods ranging from de novo to homology-based
approaches have been applied to members of the GPCR family6, 7. Until recently, much of
GPCR homology modeling efforts have been based on the templates of bovine rhodopsin and
bacteriorhodopsin, with refinement of the models by molecular dynamics simulations, ligand
docking, and incorporation of additional biochemical and biophysical data8–12. The refinement
step is necessary in building accurate models, especially around the ligand-binding site, due
to the expected structural differences both among members of the family resulting from the
generally low sequence identity and the large diversity of ligands accommodated within the
family7, 13–15, and among various conformational states associated with the different ligand
efficacy16–18.
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The most recently solved GPCR structure is the 2.6 Å crystal structure of the human adenosine
A2A receptor bound to an antagonist19. Adenosine receptors belong to the class A rhodopsin-
like GPCR family, and are implicated as promising therapeutic targets in a wide range of
conditions, including cerebral and cardiac ischaemic diseases, sleep disorders, immune and
inflammatory disorders, and cancer20. The A2A structure shows an overall seven
transmembrane helix structural similarity to the rhodopsin and adrenergic receptor structures,
with shifts in the positions and orientations of the helices and a markedly different structure of
the extracellular loops19.
To evaluate the current progress in GPCR structure prediction and docking, we carried out a
community-wide blind prediction experiment (GPCR Dock 2008) in coordination with the
release of the human adenosine A2A receptor structure in October 200819. GPCR Dock 2008
was organized in a similar manner as the CASP and CAPRI experiments21, 22, and was aimed
to assess the current status of GPCR structure modeling and docking, as well as to highlight
areas for future efforts in method development. In this paper, we report the results of the
assessment together with our analysis of the current status of GPCR structure and ligand
docking predictions.
GPCR Dock 2008
In August 2008, prior to the publication of the human adenosine A2A structure in October
200819, participating predictors were asked to blindly predict and submit up to ten ranked
models of the human A2A receptor in complex with the ligand ZM241385, starting from the
amino acid sequence of the receptor and a 2D structure of the ligand. A total of 63 different
individuals initially registered, with 206 models submitted by 29 different individuals in the
final data set. Note that 37 of the 206 submitted models were either missing the ligand or had
incorrect bond connectivity for the ligand. We assessed the remaining 169 models for the
prediction accuracy of the ligand binding mode, and all 206 models for the prediction accuracy
of the receptor alone.
Assessment criteria
RMSD (root mean square deviation) is used as a quantitative measure of the similarity
between two superimposed atomic coordinates, and is calculated by
where δ is the distance between N pairs of equivalent atoms from the two coordinates.
RMSD values (units of Å) can be calculated for any type and subset of atoms, e.g. Cα atoms
of proteins (Cα RMSD) for all residues, for residues in the transmembrane helices or the
loops; heavy atoms of small-molecule ligands (ligand RMSD).
Z-score is a standard dimensionless score that normalizes a value with respect to the sample
mean and standard deviation, and is defined by
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where x is the raw value, μ is the mean and σ is the standard deviation.
Assessment criteria are dependent on the purpose of the generated models. Given the primary
value of the GPCR structural models in expanding our knowledge in basic molecular
recognition and their potential use in design and development of new small molecules, the
quality of the models was primarily assessed by the accuracy of the ligand binding mode.
Particular attention and care was made towards the fact that the crystal structure is a static
structure with positional errors, and the value of modeling is ultimately to guide drug discovery
and biological insight. Our numerical measure of accuracy for the ligand binding mode was
based on two metrics, ligand RMSD and the number of correct receptor-ligand contacts.
Neither metric alone was sufficient to capture the accuracy of prediction around the ligand-
binding site; hence, both were used and combined into a z-score scoring scheme to rank the
models.
The ligand RMSD between model and crystal structure is calculated as the coordinate root
mean-square deviation (RMSD) for the 25 non-hydrogen atoms of ZM241385 after
superimposing the protein Cα atoms of the model and the crystal structure. In addition, the
ligand RMSD is also calculated excluding the phenoxy group of ZM241385 that has high B-
factor values. The number of correct contacts is counted as the number of correctly predicted
native contacts observed between protein atoms and the ligand. A native contact is defined as
any inter-atomic distance within 4 Å of the ligand in the crystal structure. There are 75 such
receptor-ligand contacts, and an additional 15 contacts formed with water.
The models were ranked by assigning a combined mixed z-score to each model. The combined
z-score was calculated as the average of z-scores for ligand RMSD and the number of correct
contacts: Zcombined=(−ZLigandRMSD+ ZN _ CorrectContacts)/2. The z-scores for ligand RMSD and
the number of correct contacts were computed in two passes as follows: i) assign a z-score to
each model using the average and standard deviation values from all models, ii) re-compute
the average and standard deviation excluding models with z-scores more than two standard
deviations above (for ligand RMSD) and below (for the number of correct contacts) the
average, iii) re-assign a z-score to each model using the revised average and standard deviation
values obtained in step ii. The best model, i.e. the model with the highest combined z-score,
from each group was analyzed.
Overall results
The submitted models show a wide distribution in prediction accuracy of the ligand binding
mode, with average values of 9.5 Å (s.d. 3.8 Å) for ligand RMSD and 4 (s.d. 7) for the number
of correct contacts (Figure 1A).. These statistics indicate that the majority of the submitted
models do not predict the ligand position and the binding interactions very accurately.
Furthermore, the lack of strong correlation between ligand RMSD and binding site RMSD
(Figure 1B), e.g. models with <4.0 Å binding site RMSD have a range of 2.8 to 17.2 Å ligand
RMSD, suggests that the performance of some ligand docking methods is poor and can be
improved.
Very few models score well in both ligand RMSD and the number of correct contacts (only 13
out of the 169 total receptor-ligand models have >1 combined z-score, compared to 40 models
that score well solely in ligand RMSD, ZligandRMSD <−1.0). For models with relatively low
ligand RMSD values but small number of correct contacts, the inaccuracy in binding
interactions may be attributed to errors in the sidechain placement of the ligand-binding
residues. Although nearly a third of the models capture the hydrogen bonding interaction
between the N2536.55 sidechain and the exocyclic N15 atom of the ligand (44 out of 169 models
have <4 A N253 OD1 – ZM241385 N15 interaction distance), other key receptor-ligand
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interactions such as the aromatic stacking interaction between the F1685.29 sidechain and the
bicyclic ring of the ligand are not captured well in most models (Figure 2).
While the overall outcome clearly shows that there are remaining challenges in accurately
predicting the ligand binding mode, the quality of the predictions for the receptor alone appear
to be much higher: 4.2 ± 0.9 Å for the receptor Cα RMSD, and 2.8 ± 0.5 Å for the
transmembrane (TM) helices Cα RMSD; loop regions, with the exception of ICL1 (intracellular
loop 1), are not modeled accurately in the majority of the models (Figure 3A,B and Figure 4).
It is notable that some groups that accurately predict the TM region of the receptor do not
predict the ligand binding mode very well (TM Cα RMSD: 2.0 Å for Pogozheva/Lomize, and
2.1 Å for Horst/Roy), indicating that the methods for modeling the receptor and docking the
ligand can be generally considered as distinct steps in the generation of models for the receptor-
ligand complex.
Model examples
Despite the apparent difficulty in accurately predicting the receptor-ligand interactions, some
models had consistent features with the crystal structure, although model ranking continues to
be one of the most challenging areas of development. Here, we focus on the predictions from
the top ten groups, ranked according to the combined z-score, and assess the model quality at
greater details (Figure 5). Note that, with predictions for only one target, the statistical
significance of the group ranking cannot be judged, as is typically done in CASP experiments
by a head-to-head comparison on common targets between the top groups23. To further support
our selection of the best predictions, we ranked all models using an alternative metric, binding
site contactRMSD, which treats all ligand-binding residues with equal weight, and is an RMSD
of receptor-ligand contact distance over all ligand-binding residues. We found that both the z-
score ranking and the contactRMSD ranking agree on the selection of the best model, and the
majority of other top predictions.
The best model (Costanzi) among all submitted models has a ligand RMSD of 2.8 Å RMSD
and 34 of 75 correct contacts (Figure 6A and Table I). The ligand is modeled in a native-like
binding pose, with an extended conformation and a nearly perpendicular orientation to the
membrane plane. The model accurately predicts some of the key receptor-ligand interactions:
it captures the hydrogen bonding interaction between the N2536.55 sidechain and the exocyclic
amino group (N15 atom) of the ligand, and the aromatic stacking interaction between the
F1685.29 sidechain and the bicyclic triazolotriazine core of the ligand. Compared to the crystal
structure, the ligand in the model is positioned deeper in the binding pocket, bringing the furan
ring closer to TM helices III and V. The inaccuracy in the ligand position is most likely due to
errors in the sidechain positions of the two crucial ligand-binding residues (F1685.29 and
E1695.30) in ECL2 (extracellular loop 2) and the sidechain orientation of M1775.38 at the
extracellular end of TM helix V: the aromatic ring of F1685.29, which interacts with the bicyclic
ring, is positioned too deeply; the adjacent E1695.30 forms a hydrogen bonding interaction with
the hydroxyl group in the phenolic substituent instead of the exocyclic N15 atom near the
bicyclic ring; the sidechain of M1775.38 is not oriented toward the binding cavity. In addition,
the family conserved disulfide bond C773.25 – C1665.27 is predicted accurately, but the
disulfide bond in ECL3 C2596.61 – C2626.64 is not, presumably contributing to the inaccuracy
in the sidechain orientation of H2646.66, which is not pointed toward the binding site.
The best predictions from the top six groups (Costanzi, Katritch/Abagyan, Lam/Abagyan,
Davis/Barth/Baker, Maigret, Jurkowski/Elofsson) highlight the successes and difficulties in
accurately predicting the ligand binding pose and receptor-ligand interactions (Figures 6B,C,D
and Table I). The extended ligand conformation is accurately predicted in all six models, and
the nearly perpendicular orientation is captured in four of the six models. The hydrogen bonding
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interaction between the N2536.55 sidechain and the exocyclic N15 atom of the ligand is
correctly modeled in four models; however, in one of the four, the ligand makes no interaction
with residues in ECL2. The aromatic stacking interaction between the F1685.29 sidechain and
the bicyclic ring of the ligand is correctly modeled in four models; however, in all four models,
the ligand is positioned too deeply in the binding pocket, and the M1775.38 sidechain is not
oriented toward the binding cavity. There is one model that does not accurately capture either
the hydrogen bonding interaction with N2536.55 or the aromatic stacking interaction with
F1685.29, while five of the six models accurately predict the family conserved disulfide bond
C773.25 – C1665.27. None of the six models capture the hydrogen bonding interaction between
E1695.30 in ECL2 and the exocyclic N15 atom of the ligand.
Other models that ranked near the top (Kanou, Goddard, Bologa, Olson) are slightly less
accurate but show similar trends as the top six models in their ability to accurately predict the
ligand binding mode (Table I). The ligand is modeled in a native-like extended conformation
in three of the four models. The hydrogen bonding interaction between the N2536.55 sidechain
and the exocyclic N15 atom of the ligand is modeled accurately in three of the four models;
whereas, the aromatic stacking interaction between the F1685.29 sidechain and the bicyclic ring
of the ligand is modeled accurately in only one of the four models. The family conserved
disulfide bond C773.25 – C1665.27 is captured in two models. Remarkably, one of the models
(Goddard) accurately places the E1695.30 sidechain proximal to the exocyclic N15 atom of the
ligand, and almost captures the hydrogen bonding interaction, even though the overall ECL2
conformation is inaccurate.
The best predictions were generally not ranked as the best models by the predictors at the time
of model submission prior to the release of the crystal structure (Table I). Only two of the six
best models were ranked first, and three of the six groups show a weak correlation between
their model ranking and the model quality as assessed by the combined z-score for the accuracy
around the ligand-binding site. Furthermore, the additional models submitted by the six groups
are generally of lower quality than the best predictions (Table I). Only one of the six best models
has a z-score that is within one standard deviation of the group average z-score.
Status of GPCR structure modeling and docking
The assessment of the submitted models shows that the best participating methods have the
ability to predict close native-like ligand binding, but with limitations in capturing all of the
key receptor-ligand interactions and correctly estimating model quality by ranking. The
majority of the submitted models are quite far from achieving a native-like ligand binding pose.
The most challenging aspect of GPCR structure prediction highlighted in this assessment seems
to be in accurately modeling the ligand interactions with residues in the extracellular loop
regions. This result is not surprising given the lack of structural homology in the loops among
the known GPCR structures24, and the generally difficult task of modeling loops25, 26.
The most successful prediction methods relied on homology modeling approaches based on
the template structures of β-adrenergic receptors, and in some cases with the additional template
structures of rhodopsin, (PDB IDs: 2RH1 (β2AR), 2VT4 (β1AR), 1U19 (bovine Rhod), 2Z73
(squid Rhod)) to generate models of the receptor, followed by docking of the ligand to one or
more receptor models using small-molecule docking programs such as Glide27, ICM28,
GOLD29, and AutoDock30 (see Supplementary Information for description of prediction
methods). The alignment of the human A2A sequence to the template structure seemed to have
been straightforward, given the family conserved motifs and residues in the TM helices31. The
ECL2 was modeled by de novo approaches in many of the top predictions (Katritch/Abagyan,
Lam/Abagyan, Davis/Barth/Baker, Jurkowski/Elofsson, Goddard), but only partially modeled
in the best prediction (Costanzi) for a short segment of eight residues, located N-terminus to
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TM helix V, that includes the disulfide-bond-forming C1665.27. Some of the criteria used to
select and rank the final receptor-ligand complex models were: docking scores, conformational
energy of the complex, agreement with mutagenesis and structure-activity relationship data,
and binding selectivity studied by virtual ligand screening or by modeling other subtypes of
adenosine receptor.
The reliability of the homology modeling approach depends on the availability of suitable
templates32. The results of the current assessment show that the structures of β-adrenergic
receptors alone or together with rhodopsin were suitable transmembrane templates in
predicting the general structure of the adenosine A2A receptor. However, given the expected
structural diversity in class A GPCRs, it is unclear whether the current set of techniques applied
to the structure prediction of the A2A–ZM241385 complex would result in a similar level of
accuracy for the prediction of other GPCRs, especially for those belonging to subfamilies that
are phylogenetically distant from the amine and the opsin receptor clusters33. We believe the
database of GPCR structures needs to expand further to provide suitable templates for accurate
modeling of those other receptors.
The inaccuracies in homology models can arise from errors in side-chain packing, main-chain
shifts in aligned regions, errors in unaligned loop regions, misalignments, and incorrect
templates34. These errors relate to the issue of “adding value” to the template structure, which
was addressed in the recent CASP experiment35, and also seems to be applicable to GPCR
modeling. Indeed, ligand interactions with residues located in structurally divergent regions
from the templates are consistently not modeled accurately in all of the six best predictions:
hydrogen bonding interaction between E1695.30 in ECL2 and the exocyclic N15 atom of the
ligand is not captured, and the sidechains of H2646.66 in ECL3 and M1775.38 in the extended
bulge structure unique to A2A at the extracellular end of TM helix V are not oriented toward
the binding site. An exception is the aromatic stacking interaction between F1685.29 in ECL2
and the bicyclic ring of the ligand, which is correctly modeled in some of the predictions.
F1685.29 is located in the loop, but it is structurally homologous to F1935.32 which interacts
with the carbazole heterocycle of the ligand carazolol in the β2AR structure, hence modeling
of this interaction may have been guided by homology. Interestingly, F1685.29 is modeled more
accurately than E1695.30 even though mutagenesis data shows mutation of E1695.30 to alanine
reduces the affinity for both antagonists and agonists36, and no data is available for F1685.29.
The inaccuracy in the orientation of the ligand binding pose, e.g. the parallel orientation with
the phenolic substituent positioned close to TM helices II and III, may in part be due to the
inaccurate modeling of the helical shifts in TM helices I, II, and III. The helical shifts alter the
location of the binding pocket and redefine the pocket size and shape19; thus, it is expected
that accurately modeling the helical shifts would contribute to a better prediction of the ligand
binding pose. The helical shifts were most accurately modeled by an effective use of multiple
template structures of rhodopsin and β-adrenergic receptors (Pogozheva/Lomize), or an all-
atom refinement approach implemented by the ROSETTA program using a physically realistic
model that recapitulates protein interatomic and protein-solvent interactions in the membrane
environment37 (Davis/Barth/Baker).
Other sources of error include not modeling the water molecules that are either structurally
important or directly involved in ligand binding interactions3. The ligand binding cavity in the
A2A–ZM241385 structure has four ordered water molecules19, yet none of the submitted
predictions included water molecules. We tried re-docking the ligand to the crystal structure
using ICM28 and found that a native-like binding pose (within 1 Å heavy atom RMSD for the
bicyclic ring and the furanyl substituent of the ligand, and <3.0 Å overall ligand RMSD) can
be recovered without any water molecules, which suggests that water may not be critical for
accurately predicting the ligand interactions. However, modeling water molecules together
with the ligand may contribute in general to a better prediction of the ligand binding pose or
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affinity. Additional re-docking studies with the docking protocols used by the participating
methods would help assess the effect of the water molecules, and the accuracy of the docking
methods separately from that of the receptor modeling methods.
Lastly, it is interesting that the best model was from the Costanzi group who worked previously
with adenosine receptor modeling and docking. Their domain knowledge on the adenosine
receptor may have helped with the interpretation of the mutagenesis and ligand interaction data
and such domain knowledge is almost certainly critical.
Conclusion
Accurate prediction of GPCR structure and ligand interactions clearly remains a challenge
despite the increase in the number of experimentally solved GPCR structures within the last
year. Assessment of these predictions highlights similar issues addressed by the CASP
predictions for template-based modeling targets, i.e. the difficulty in loop modeling, refinement
and improvement over the best available template, and model ranking. Accurate modeling of
the structurally divergent region such as the extracellular loops, disulfide bond formation
affecting helix residue registry, and the helical shifts in the TM region seems to be particularly
critical for accurately predicting the key ligand interactions in GPCRs, and this area is perhaps
the most in need of technological development. Progress in GPCR modeling and docking will
require further improvements in the current prediction methods to “add value” to the best
available templates and generate models that will be more useful for applications in structure-
based drug design.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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RMSD of submitted models. (A) Distribution of ligand RMSD (gold bars) and protein Cα
RMSD (blue bars) for all models. (B) A scatterplot of ligand RMSD (y axis) versus binding
site RMSD (x axis) for all models. The binding site RMSD values are calculated for heavy
atoms of the binding site residues (F1685.29, E1695.30, M1775.38, W2466.48, L2496.51,
H2506.52, N2536.55, H2646.66, M2707.35) after the models are superimposed to the crystal
structure using the protein Cα atoms.
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Statistics of the two key receptor-ligand interactions in all models. (A) The hydrogen bonding
interaction with N2536.55 and the aromatic stacking interaction with F1685.29 are shown by
dashed lines with the distance measurements from the crystal structure. (B) Distribution of the
distance for the interaction between the sidechain carbonyl oxygen OD1 atom in N2536.55 and
the exocyclic N15 atom of the ligand, and the average interatomic distance for the aromatic
stacking interaction between the heavy atoms in the F1685.29 sidechain and the bicyclic ring
(atoms C11, N12, N13, C14, N15, N16, N17, C18, N19, C20) of ZM241385. (C) A scatterplot
of the distances for the hydrogen bonding interaction (y axis) versus the aromatic stacking
interaction (x axis).
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Superposition of all 206 submitted models to the crystal structure of the human adenosine
A2A receptor (PDB ID: 3EML without the T4-lysozyme). Protein Cα atom superposition
between model and crystal structure was done using the align command in PyMOL (version
1.0r2, www.pymol.org). The receptor is shown as two orthogonal views of Cα traces (A, B)
with tube thickness being proportional to the RMSD about each Cα position clearly showing
how well the TM regions were modeled and how much uncertainty are in the loop regions. (C)
A superposition of stick diagrams of the ligand (ZM241385) from 169 models, a CPK model
is used to delineate the observed position in the crystal structure. The C-terminus (residue
numbers >306) is removed from all models.
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Distribution of Cα RMSDs for TM helices I to VII (helix I: 6–34; helix II: 40–67; helix III:
73–107; helix IV: 117–142; helix V: 173–205; helix VI: 222–258; helix VII: 266–291), and
the loop regions (ICL1: 35–39; ICL2: 108–116; ECL1: 68–72; ECL2:143–172 excluding 149–
155 that are missing in the crystal structure; ECL3: 259–265).
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A scatterplot of the number of correct contacts (y axis) versus ligand RMSD (x axis) for the
best predictions from all groups. The best predictions from the top six groups are marked as
gold crosses.
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Comparison between the best models and the crystal structure around the ligand-binding site.
(A) The ligand and the ligand-binding residues F1685.29, E1695.30, M1775.38, L2496.51,
N2536.55, H2646.66 are shown for the best model (Costanzi) and the crystal structure. The
ligand is shown as sticks for the model (magenta colored carbon atoms) and semitransparent
spheres (green colored carbon atoms) for the crystal structure; the ligand-binding residues are
shown as yellow sticks for the model, and blue sticks for the crystal structure. Extracellular
(B) and side views (C) of the ligand in the binding pocket for the best predictions from the top
six groups (magenta sticks for models, and green spheres for the crystal structure). The receptor
crystal structure is in gray ribbons. The disulfide bonds are shown in orange sticks (D) The
ligand-binding residues F1685.29 and N2536.55 are shown as sticks for the best predictions from
the top six groups (yellow for models, and blue for the crystal structure). In (B), (C) and (D)
the models are labeled as a – Constanzi; b - Katritch; c - Lam; d - Davis; e - Maigret; f –
Jurkowski.
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